Will This Analyst Upgrade Help Rogers (ROG) Stock Today? (Update)

Update (9:39 a.m.): Updated with Thursday market open information.

NEW YORK (TheStreet) -- DA Davidson upgraded Rogers  (ROG) to "buy" from "neutral" and set a $69 price target. The firm notes revenue growth is coming back.

The stock was down 0.68% to $59.61 at 9:38 a.m. on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

----------

Separately, TheStreet Ratings team rates ROGERS CORP as a "buy" with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:

"We rate ROGERS CORP (ROG) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • ROG's revenue growth has slightly outpaced the industry average of 1.8%. Since the same quarter one year prior, revenues slightly increased by 9.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • ROG's debt-to-equity ratio is very low at 0.15 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 3.23, which clearly demonstrates the ability to cover short-term cash needs.
  • 42.74% is the gross profit margin for ROGERS CORP which we consider to be strong. It has increased from the same quarter the previous year. Along with this, the net profit margin of 8.46% is above that of the industry average.
  • Net operating cash flow has increased to $32.91 million or 34.23% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 0.94%.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Electronic Equipment, Instruments & Components industry. The net income increased by 127.7% when compared to the same quarter one year prior, rising from $5.06 million to $11.53 million.
  • You can view the full analysis from the report here: ROG Ratings Report

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

FDA Approves First 'Biosimilar' for Cancer Treatment

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

5 New Breast Cancer Treatments That Are Helping to Save Lives

Celgene Enters PD1 Market with BeiGene Deal

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J